Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more

PrincipalinvestigatorStart date: 2022-03-21

NCT03704714Phase 1/2Suspended

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Aggressive Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaCD20 Positive+5 more

PrincipalinvestigatorStart date: 2018-11-20

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

B-cell Non-Hodgkin Lymphoma2 Aggressive Non-Hodgkin Lymphoma1 CD20 Positive1 Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation1 Diffuse Large B-Cell Lymphoma Unclassifiable1 EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified1 High Grade B-Cell Lymphoma, Not Otherwise Specified1 Intravascular Large B-Cell Lymphoma1

Affiliations

Northwestern University

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jordan Gauthier

Fred Hutch/University of Washington Cancer Consortium

5 trials

Shared therapeutic areas:

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory B-Cell Non-Hodgkin Lymphoma+6 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score9%

Mengyang Di, MD, PhD

Fred Hutch/University of Washington Cancer Consortium

4 trials

Shared therapeutic areas:

B-cell Non-Hodgkin LymphomaEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+3 more

Similarity Score6%

Ajay Gopal

Fred Hutch/University of Washington Cancer Consortium

8 trials

Shared therapeutic areas:

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaB-cell Non-Hodgkin Lymphoma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score5%

Joseph M Tuscano

University of California, Davis

5 trials

Shared therapeutic areas:

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory B-Cell Non-Hodgkin Lymphoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score4%

Ryan Lynch

Fred Hutch/University of Washington Cancer Consortium

5 trials

Shared therapeutic areas:

Aggressive Non-Hodgkin LymphomaEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+1 more

Similarity Score4%

Mazyar Shadman

Fred Hutch/University of Washington Cancer Consortium

3 trials

Shared therapeutic areas:

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score4%

Alex F Herrera

City of Hope Medical Center

9 trials

Shared therapeutic areas:

Diffuse Large B-Cell Lymphoma UnclassifiableRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score3%

Yago L Nieto

M.D. Anderson Cancer Center

5 trials

Shared therapeutic areas:

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score3%

Geoffrey Shouse

City of Hope Medical Center

3 trials

Shared therapeutic areas:

Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score2%

Stephen D. Smith

Fred Hutch/University of Washington Cancer Consortium

3 trials

Shared therapeutic areas:

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma

Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT06723457Phase 2PrincipalInvestigator

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Polymorphic Post-Transplant Lymphoproliferative DisorderRefractory B-Cell Non-Hodgkin Lymphoma

Recruiting

NCT06242834Phase 2PrincipalInvestigator

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma

Active Not Recruiting

NCT05202782Phase 2PrincipalInvestigator

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more

Active Not Recruiting

NCT03704714Phase 1/2PrincipalInvestigator

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Aggressive Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaCD20 Positive+5 more

Suspended

All 4 trials loaded